130 related articles for article (PubMed ID: 38556751)
1. The plasma-soluble CSF1R level is a promising prognostic indicator for pediatric Langerhans cell histiocytosis.
Zhu T; Wang CJ; Lian HY; Ma HH; Wang D; Wang TY; Zhang R; Cui L; Li ZG
Pediatr Blood Cancer; 2024 Jun; 71(6):e30970. PubMed ID: 38556751
[TBL] [Abstract][Full Text] [Related]
2. CSF1R Is Required for Differentiation and Migration of Langerhans Cells and Langerhans Cell Histiocytosis.
Lonardi S; Scutera S; Licini S; Lorenzi L; Cesinaro AM; Gatta LB; Castagnoli C; Bollero D; Sparti R; Tomaselli M; Medicina D; Calzetti F; Cassatella MA; Facchetti F; Musso T; Vermi W
Cancer Immunol Res; 2020 Jun; 8(6):829-841. PubMed ID: 32238382
[TBL] [Abstract][Full Text] [Related]
3. Circulating cell-free BRAF
Héritier S; Hélias-Rodzewicz Z; Lapillonne H; Terrones N; Garrigou S; Normand C; Barkaoui MA; Miron J; Plat G; Aladjidi N; Pagnier A; Deville A; Gillibert-Yvert M; Moshous D; Lefèvre-Utile A; Lutun A; Paillard C; Thomas C; Jeziorski E; Nizard P; Taly V; Emile JF; Donadieu J
Br J Haematol; 2017 Aug; 178(3):457-467. PubMed ID: 28444728
[TBL] [Abstract][Full Text] [Related]
4. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ
Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
[TBL] [Abstract][Full Text] [Related]
5. Expression of GM-CSF receptor by Langerhans' cell histiocytosis cells.
Emile JF; Fraitag S; Andry P; Leborgne M; Lellouch-Tubiana A; Brousse N
Virchows Arch; 1995; 427(2):125-9. PubMed ID: 7582241
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory serum cytokines and chemokines increase associated with the disease extent in pediatric Langerhans cell histiocytosis.
Morimoto A; Oh Y; Nakamura S; Shioda Y; Hayase T; Imamura T; Kudo K; Imashuku S;
Cytokine; 2017 Sep; 97():73-79. PubMed ID: 28582647
[TBL] [Abstract][Full Text] [Related]
7. Association between clinicopathologic characteristics and BRAF
Huang H; Lu T; Sun Y; Li S; Li J; Xu K; Feng RE; Xu ZJ
Thorac Cancer; 2019 Oct; 10(10):1984-1992. PubMed ID: 31441596
[TBL] [Abstract][Full Text] [Related]
8.
Ozer E; Sevinc A; Ince D; Yuzuguldu R; Olgun N
Pediatr Dev Pathol; 2019 Oct; 22(5):449-455. PubMed ID: 31072207
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults.
Milne P; Bigley V; Bacon CM; Néel A; McGovern N; Bomken S; Haniffa M; Diamond EL; Durham BH; Visser J; Hunt D; Gunawardena H; Macheta M; McClain KL; Allen C; Abdel-Wahab O; Collin M
Blood; 2017 Jul; 130(2):167-175. PubMed ID: 28512190
[TBL] [Abstract][Full Text] [Related]
10. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.
McClain KL; Picarsic J; Chakraborty R; Zinn D; Lin H; Abhyankar H; Scull B; Shih A; Lim KPH; Eckstein O; Lubega J; Peters TL; Olea W; Burke T; Ahmed N; Hicks MJ; Tran B; Jones J; Dauser R; Jeng M; Baiocchi R; Schiff D; Goldman S; Heym KM; Wilson H; Carcamo B; Kumar A; Rodriguez-Galindo C; Whipple NS; Campbell P; Murdoch G; Kofler J; Heales S; Malone M; Woltjer R; Quinn JF; Orchard P; Kruer MC; Jaffe R; Manz MG; Lira SA; Parsons DW; Merad M; Man TK; Allen CE
Cancer; 2018 Jun; 124(12):2607-2620. PubMed ID: 29624648
[TBL] [Abstract][Full Text] [Related]
11. Clinical and prognostic features of Langerhans cell histiocytosis in adults.
Sato A; Kobayashi M; Yusa N; Ogawa M; Shimizu E; Kawamata T; Yokoyama K; Ota Y; Ichinohe T; Ohno H; Mori Y; Sakaida E; Kondo T; Imoto S; Nannya Y; Mitani K; Tojo A
Cancer Sci; 2023 Sep; 114(9):3687-3697. PubMed ID: 37364599
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosis.
Wang D; Chen XH; Wei A; Zhou CJ; Zhang X; Ma HH; Lian HY; Zhang L; Zhang Q; Huang XT; Wang CJ; Yang Y; Liu W; Wang TY; Li ZG; Cui L; Zhang R
Orphanet J Rare Dis; 2022 Apr; 17(1):151. PubMed ID: 35379272
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.
Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M
Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272
[TBL] [Abstract][Full Text] [Related]
14. Apparent Lack of
Kemps PG; Zondag TC; Steenwijk EC; Andriessen Q; Borst J; Vloemans S; Roelen DL; Voortman LM; Verdijk RM; van Noesel CJM; Cleven AHG; Hawkins C; Lang V; de Ru AH; Janssen GMC; Haasnoot GW; Franken KLMC; van Eijk R; Solleveld-Westerink N; van Wezel T; Egeler RM; Beishuizen A; van Laar JAM; Abla O; van den Bos C; van Veelen PA; van Halteren AGS
Front Immunol; 2019; 10():3045. PubMed ID: 31998317
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of clinical, iconographical and pathological characteristics, prognosis and treatment methods for 35 cases of Langerhans cell histiocytosis].
Yang H; Han XP; Li BJ; Sun L; Zhu HY; Li F; Wang QS; Huang WR; Bo J; Zhao Y; Li HH; Wang SH; Yu L; Jing Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1109-14. PubMed ID: 25130838
[TBL] [Abstract][Full Text] [Related]
16. High Prevalence of
Liu X; Zhang Y; Zhou CX
Int J Surg Pathol; 2019 Dec; 27(8):836-843. PubMed ID: 31203679
[TBL] [Abstract][Full Text] [Related]
17. High levels of plasma interleukin-17A are associated with severe neurological sequelae in Langerhans cell histiocytosis.
Ismail MB; Åkefeldt SO; Lourda M; Gavhed D; Aricò M; Henter JI; Delprat C; Valentin H
Cytokine; 2020 Feb; 126():154877. PubMed ID: 31629106
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of interleukin-1 receptor antagonist and tumor necrosis factor-alpha are elevated in children with Langerhans cell histiocytosis.
Rosso DA; Ripoli MF; Roy A; Diez RA; Zelazko ME; Braier JL
J Pediatr Hematol Oncol; 2003 Jun; 25(6):480-3. PubMed ID: 12794527
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes and prognostic risk factors of Langerhans cell histiocytosis in children: Results from the BCH-LCH 2014 protocol study.
Cui L; Wang CJ; Lian HY; Zhang L; Ma HH; Wang D; Chen FF; Zhang Q; Yang Y; Wei A; Huang XT; Zhu T; Wang TY; Li ZG; Zhang R
Am J Hematol; 2023 Apr; 98(4):598-607. PubMed ID: 36594188
[TBL] [Abstract][Full Text] [Related]
20. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.
Berres ML; Lim KP; Peters T; Price J; Takizawa H; Salmon H; Idoyaga J; Ruzo A; Lupo PJ; Hicks MJ; Shih A; Simko SJ; Abhyankar H; Chakraborty R; Leboeuf M; Beltrão M; Lira SA; Heym KM; Bigley V; Collin M; Manz MG; McClain K; Merad M; Allen CE
J Exp Med; 2014 Apr; 211(4):669-83. PubMed ID: 24638167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
